Next Phase Newsletter

Based in the US, a venture capital firm invests in early-stage life sciences and healthcare. The firm seeks early-stage investment opportunities from seed to series A, generally investing $50k to $1.5M in the initial round, with potential for follow-on investments up to $3M. The firm is focused regionally based companies (those close to their office) but also seek opportunities globally. The firm is open to both leading and co-investing. 
 
The firm invests in medical devices, diagnostics and digital health. The firm is open to considering all subsectors and indications. 
 
While the firm can invest in companies based elsewhere under certain circumstances, the firm is primarily focused on companies in the same state. The firm is active in supporting their portfolio companies and will consider taking a board seat on a case-by-case basis. Additionally, the firm is open to engages with entrepreneurs and founders at a very early stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A globally diversified healthcare venture capital firm headquartered in Singapore. The firm’s mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU.  

The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm based in Australia is backed by one of Australia’s largest family offices. With its current fund, the firm will focus exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies – while the firm has a focus on supporting the Australian ecosystem, the firm is open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. 
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment group located in the U.S. and Europe invests in early-stage life science companies from Seed to Series C. Typical check size can be up to $60M USD and varies depending on the fit. The firm makes investments to global companies acting as both a lead and co-investor. 
 
The firm is seeking to invest in biotech therapeutics, diagnostics, and medical devices. The firm is indication- and sub sector-agnostic and can fund companies from Phase I to Phase IV. 
 
The firm does not require to take a board seat, but rather seeks to run the clinical trial programs in exchange. The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A family office based in the US makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania. 
 
The firm funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An angel syndicate headquartered in Baltimore, Maryland. The group invests in device, diagnostics, and digital health companies globally. The group will invest as early as Seed rounds up to Series B. Typical check size falls between $250k-1M USD and prefers to co-invest. The firm will invest through equity or convertible notes. 
 
The firm invests in medical devices, digital health, and diagnostics. The firm does not invest in therapeutics. In terms of devices, the firm is open to all classes of devices. Current interest is in cardiology, structural heart, and neurology, but the firm is indication-agnostic. Although there is preference with earlier stages of development, the firm is stage-agnostic. 
 
The firm may take a board seat on a case-by-case basis. The firm requires companies to have at least one full time executive.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A China-based pharmaceutical company has a headcount of over 7,000 and has more than 40 branches and subsidiaries around the world. The company’s main businesses are in API and generics, although they are rapidly expanding into innovation drug areas such as small molecule drugs, biologics, and cell therapies. The firm has a US subsidiary, an integrated business with capabilities in R&D, manufacturing, and Sales and Marketing. The firm sells generic drugs to major pharmacy chains like CVS and Walgreens, department stores like Walmart and Costco, major grocery stores, etc. 

The firm also has an investment subsidiary that conducts equity investments and BD activities (in-licensing, supplier/distributor agreements, etc.) for both the China and US markets. 
 
The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilar. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA). 

While the firm welcomes proposals on various equity investment and BD opportunities, the firm is currently also interested specifically in the following: 

-Late clinical stage assets that can be in-licensed and introduced to the China market; 

-Technologies that can be used to improve API production; 

-Injectable drugs; 

The firm is also interested in distribution rights in China (for both innovation and generic drugs) and in the US (mainly for generic drugs). 
 
The firm has no specific company or management team requirements.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.